Federated Hermes Inc. Lowers Holdings in Gamida Cell Ltd. (NASDAQ:GMDA)

Posted by on Mar 11th, 2023

Federated Hermes Inc. decreased its holdings in Gamida Cell Ltd. (NASDAQ:GMDA – Get Rating) by 17.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,538,348 shares of the company’s stock after selling 330,548 shares during the quarter. Federated Hermes Inc. owned 2.60% of Gamida Cell worth $2,446,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Virtu Financial LLC purchased a new position in shares of Gamida Cell in the second quarter valued at approximately $36,000. Levin Capital Strategies L.P. purchased a new position in shares of Gamida Cell in the third quarter valued at approximately $40,000. Cubist Systematic Strategies LLC purchased a new position in shares of Gamida Cell in the second quarter valued at approximately $42,000. Stock Yards Bank & Trust Co. purchased a new position in shares of Gamida Cell in the second quarter valued at approximately $62,000. Finally, Bank of America Corp DE raised its holdings in Gamida Cell by 539.0% in the first quarter. Bank of America Corp DE now owns 15,214 shares of the company’s stock valued at $63,000 after acquiring an additional 12,833 shares in the last quarter. Hedge funds and other institutional investors own 56.19% of the company’s stock.

Analyst Upgrades and Downgrades

GMDA has been the topic of several analyst reports. Needham & Company LLC reduced their target price on shares of Gamida Cell from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Tuesday, November 22nd. Oppenheimer reduced their target price on shares of Gamida Cell from $15.00 to $10.00 and set an “outperform” rating on the stock in a report on Tuesday, November 15th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, Gamida Cell currently has an average rating of “Buy” and an average target price of $12.80.

Gamida Cell Stock Performance

Shares of Gamida Cell stock opened at $1.54 on Friday. The firm’s fifty day simple moving average is $1.53 and its 200-day simple moving average is $1.73. The stock has a market capitalization of $114.55 million, a price-to-earnings ratio of -1.20 and a beta of 1.67. Gamida Cell Ltd. has a 12 month low of $1.10 and a 12 month high of $4.72. The company has a debt-to-equity ratio of 5.31, a current ratio of 2.76 and a quick ratio of 2.76.

About Gamida Cell

(Get Rating)

Gamida Cell Ltd. engages in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The firm offers Omidubicel, an investigational product with potential as a life-saving alternative for patients in need of a bone marrow transplant, and a line of modified and unmodified nicotinamide-enabled natural killer cells targeted at solid tumor and hematological malignancies.

Featured Articles

Institutional Ownership by Quarter for Gamida Cell (NASDAQ:GMDA)

Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.